Malaga Cove Capital LLC Purchases New Stake in Eli Lilly and Company $LLY

Malaga Cove Capital LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 362 shares of the company’s stock, valued at approximately $282,000.

Other large investors have also recently made changes to their positions in the company. Lazard Freres Gestion S.A.S. boosted its stake in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after buying an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after acquiring an additional 39 shares during the last quarter. Capital Advisors Inc. OK lifted its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after acquiring an additional 429 shares during the period. Family CFO Inc purchased a new position in Eli Lilly and Company in the second quarter worth $54,000. Finally, Duquesne Family Office LLC boosted its position in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 1.5%

Shares of LLY opened at $923.35 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $955.46. The business has a 50-day moving average of $799.97 and a 200 day moving average of $775.76. The firm has a market cap of $872.92 billion, a P/E ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 4,314 shares of company stock valued at $2,766,929 in the last quarter. Corporate insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LLY shares. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a research report on Sunday, August 17th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $960.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.